The Types segment classifies intolerance tests by underlying technology: serological, molecular, and cell‑based assays, each with sub‑categories that influence adoption rates and pricing dynamics. Serological tests, which detect IgG or IgE antibodies, dominate the market with an estimated 55% share due to their established workflow, ease of integration into existing lab platforms, and relatively low per‑test cost. Within this group, multiplex panels and single‑analyte kits serve different clinical needs, affecting volume distribution. Molecular tests, representing about 30% of sales, employ DNA‑based methods such as PCR to identify genetic variants linked to metabolic intolerance; higher analytical specificity drives premium pricing and adoption in specialized research settings. Cell‑based assays, accounting for the remaining 15%, measure functional responses of patient‑derived cells to suspected allergens, offering mechanistic insight but requiring sophisticated infrastructure, which limits widespread use. The proportional contribution of each type delineates the market’s revenue architecture and informs strategic investment decisions.